✦ LIBER ✦

Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

✍ Scribed by A. Kong; V. Calleja; P. Leboucher; A. Harris; P. Parker; B. Larijani

Book ID: 119598441
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 85 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)71210-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

485 POSTER Activation of alternative HER

485 POSTER Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

✍ A. Kong; V. Calleja; P. Leboucher; A. Harris; P. Parker; B. Larijani 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Breast cancer cells with acquired resist

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

✍ Nicola Normanno; Manuela Campiglio; Monica R. Maiello; Antonella De Luca; Mario 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 408 KB

Ron Receptor Tyrosine Kinase Activation

Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines

✍ McClaine, Rebecca J.; Marshal, Aaron M.; Wagh, Purnima K.; Waltz, Susan E. 📂 Article 📅 2010 🏛 Neoplasia Press 🌐 English ⚖ 428 KB

Activating and resistance mutations of E

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

✍ Gazdar, A F 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 213 KB

AZD3409 inhibits the growth of breast ca

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

✍ Monica R. Maiello; Amelia D’Alessio; Antonella De Luca; Adele Carotenuto; Anna M 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 290 KB

The MEK/MAPK pathway is involved in the

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)